Select β-Lactam Combinations Exhibit Synergy against Mycobacterium abscessus In Vitro
- 1 April 2019
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 63 (4)
Abstract
Mycobacterium abscessus (Mab) is a nontuberculous mycobacterium that causes invasive pulmonary infections in patients with structural lung disease. Mab is intrinsically resistant to several classes of antibiotics and an increasing number of strains isolated from patients exhibit resistance to most antibiotics considered for treatment of infections by this mycobacterium. Therefore, there is an unmet need for new regimens with improved efficacy to treat this disease. Synthesis of the essential cell wall peptidoglycan in Mab is achieved via two enzyme classes, L,D- and D-D-transpeptidases, with each class preferentially inhibited by different subclasses of β-lactam antibiotics. We hypothesized that a combination of two β-lactams that comprehensively inhibit the two enzyme classes will exhibit synergy in killing Mab. Paired combinations of antibiotics tested for in vitro synergy against Mab included dual β-lactams, a β-lactam and a β-lactamase inhibitor, and a β-lactam and a rifamycin. Of the initial 206 combinations screened, 24 pairs exhibited synergy. 13/24 pairs were combinations of two β-lactams. 12/24 pairs brought the minimum inhibitory concentrations of both drugs to within the therapeutic range. Additionally, synergistic drug pairs significantly reduced the frequency of selection of spontaneous resistant mutants. These novel combinations of currently-available antibiotics may offer viable immediate treatment options against highly-resistant Mab infections.Keywords
All Related Versions
Funding Information
- HHS | National Institutes of Health (R21 AI121805)
- HHS | National Institutes of Health (T32 AI007291)
- Cystic Fibrosis Foundation (LAMICH17GO)
This publication has 50 references indexed in Scilit:
- Kinetic Features of L,D-Transpeptidase Inactivation Critical for β-Lactam Antibacterial ActivityPLOS ONE, 2013
- Whole-genome sequencing to identify transmission of Mycobacterium abscessus between patients with cystic fibrosis: a retrospective cohort studyThe Lancet, 2013
- Management of Nontuberculous Mycobacterial (NTM) Lung DiseaseSeminars in Respiratory and Critical Care Medicine, 2013
- Inactivation of Mycobacterium tuberculosis l , d -Transpeptidase Ldt Mt1 by Carbapenems and CephalosporinsAntimicrobial Agents and Chemotherapy, 2012
- Mycobacterium abscessus: a new antibiotic nightmareJournal of Antimicrobial Chemotherapy, 2012
- Inactivation Kinetics of a New Target of β-Lactam AntibioticsJournal of Biological Chemistry, 2011
- The Peptidoglycan of Mycobacterium abscessus Is Predominantly Cross-Linked by l , d -TranspeptidasesJournal of Bacteriology, 2011
- A Novel Gene,erm(41), Confers Inducible Macrolide Resistance to Clinical Isolates ofMycobacterium abscessusbut Is Absent fromMycobacterium chelonaeAntimicrobial Agents and Chemotherapy, 2009
- Rifamycin antibiotic resistance by ADP-ribosylation: Structure and diversity of ArrProceedings of the National Academy of Sciences, 2008
- Synergy assessed by checkerboard a critical analysisDiagnostic Microbiology and Infectious Disease, 1993